Show summary Hide summary
- What recent research shows about aspirin and cancer
- Key trials and how they differ
- Why might aspirin raise cancer-related deaths?
- What experts and guidelines recommend now
- How patients should approach aspirin use
- Limitations of the evidence to date
- Practical takeaways for clinicians
- What researchers plan next
Low-dose aspirin has long been used to protect the heart. New analyses now suggest it does not lower the chance of getting cancer. But some randomized trials have reported a puzzling signal: higher rates of cancer-related death among people taking daily low-dose aspirin, especially older adults. That finding has stirred debate among clinicians and patients weighing aspirin for prevention.
What recent research shows about aspirin and cancer
Multiple large studies and pooled analyses have examined whether taking 75–100 mg of aspirin daily affects cancer outcomes. The general pattern is mixed:
Eggs every day for months: simple check reveals shocking blood test result
Popular childhood food ingredient may raise adult anxiety: study
- Several trials found no consistent reduction in cancer incidence tied to routine low-dose aspirin.
- In at least one prominent randomized trial of older adults, participants assigned to aspirin had a higher rate of death from cancer.
- Other trials, including those in people with diabetes or moderate cardiovascular risk, did not reproduce a clear increase in cancer mortality.
Key trials and how they differ
Not all studies are the same. Differences in participant age, health status, and follow-up times matter.
Age and health at the start
- Trials enrolling older adults often showed the strongest signal for higher cancer deaths.
- Studies of middle-aged people or those with specific risk profiles showed no similar effect.
Dose, adherence, and duration
- Most trials used low doses (around 75–100 mg daily).
- Adherence to the study drug and the length of follow-up varied.
- Cancer development and progression can take years, complicating short-term trial interpretation.
Why might aspirin raise cancer-related deaths?
Researchers offer several hypotheses, none proven:
- Aspirin could alter immune responses or inflammation in ways that affect tumor progression.
- Use in older or frail populations may unmask preexisting cancers by changing bleeding patterns or diagnostic timing.
- Statistical chance or differences in how deaths were classified may explain some findings.
No definitive biological mechanism has been confirmed to explain higher cancer mortality with low-dose aspirin.
What experts and guidelines recommend now
Medical organizations have updated guidance in recent years. The main message is cautious.
- For secondary prevention—people with prior heart attack or stroke—aspirin remains standard.
- For primary prevention—people without known cardiovascular disease—many guidelines advise against routine low-dose aspirin, especially in older adults.
- Decisions should weigh cardiovascular benefits against risks of bleeding and potential cancer-related outcomes.
How patients should approach aspirin use
Anyone taking or considering low-dose aspirin should discuss it with their clinician. Useful questions include:
- What is my real risk of heart attack or stroke in the next 10 years?
- What is my risk of major bleeding?
- Do I have conditions that change cancer risk or the way aspirin may act?
- Are there alternative ways to lower my cardiovascular risk?
Do not stop or start aspirin without medical advice. The balance of risks and benefits is personal.
Limitations of the evidence to date
Interpretation requires care. Common limitations include:
- Short follow-up relative to cancer latency.
- Variability in how deaths and causes were adjudicated.
- Differences in participant ages and baseline health.
- Potential chance findings when multiple outcomes are examined.
Practical takeaways for clinicians
Clinicians should individualize discussions and document shared decisions.
- Review aspirin use in older patients regularly.
- Prioritize evidence-based measures: blood pressure control, statins, smoking cessation.
- Consider stopping aspirin for primary prevention in patients with low cardiovascular risk or high bleeding risk.
What researchers plan next
Ongoing and planned studies aim to clarify long-term cancer outcomes by age and risk group.
- Longer follow-up of existing trials will help determine if the cancer mortality signal persists.
- Mechanistic studies will test how aspirin might influence tumor biology.
- New pooled analyses will try to harmonize data across trials to reduce uncertainty.
